5月8日 - ** 基因编辑公司Intellia Therapeutics NTLA.O股价上涨3.4%至7.54美元
** NTLA报告第一季度每股净亏损1.10美元，比去年同期的净亏损1.12美元有所收窄
** 第一季度合作收入为 1663 万美元，去年同期为 2890 万美元
** 公司表示，截至3月31日，公司拥有现金及现金等价物7.071亿美元，预计到2027年上半年还将继续运营
** 包括本交易日的走势在内，该股今年累计下跌 35.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.